LETTER TO THE EDITOR

Acceptability and feasibility of post-treatment fertility preservation in women previously treated for hematological diseases

Authors

Celine Chalas,[1] Florian Chevillon,[2] Flore Sicre de Fontbrune,[3] Nathalie Dhedin,[2] Alienor Xhaard,[3] Catherine Thieblemont,[4,5] Pauline Brice,[5] Marion Bendayan,[6,7] Benedicte Paillusson,[8] Jean-Hugues Dalle,[5,9] Beatrice Delepine,[10] Mathilde Bourdon,[5,11] Virginie Barraud-Lange,[1,2] Catherine Poirot[2#] and Nicolas Boissel[2,5#]

[1]Department of Reproductive Biology-CECOS, AP-HP, Cochin Hospital, Paris; [2]Department of Hematology, AYA Unit, AP-HP, Saint-Louis Hospital, Paris; [3]Hematology Transplant Unit, French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, APHP, Saint-Louis Hospital, Paris; [4]Department of Hematology-Oncology, AP-HP, Saint-Louis Hospital, Paris; [5]University Paris-Cité, Paris; [6]Department of Reproductive Biology, Poissy Hospital, St Germain en Laye; [7]INRAE, Paris Saclay University, UVSQ, Jouy-en-Josas; [8]Department of Reproductive Medicine, Poissy Hospital, St Germain en Laye; [9]Department of Pediatric Hematology, AP-HP, Robert Debré Hospital, Paris; [10]Department of Reproductive Biology CECOS, Reims Hospital, Reims and [11]Department of Reproductive Medicine, Cochin Hospital, Paris, France

[#]CP and NP contributed equally as senior authors.

Correspondence:
C: CHALAS - celine.chalas@aphp.fr

https://doi.org/10.3324/haematol.2025.300093

Received: October 23, 2025.
Accepted: March 18, 2026.
Early view: April 2, 2026.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license

Supplemental Table 1. Examples of mono and bifunctional alkylating agents (from Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition, 2011)

Monofunctional alkylating agents	Bifunctionnal alkylating agents
Triazenes / Hydrazines :Dacarbazine, Temozolomide…	Nitrosoureas: Carmustine (BCNU), Lomustine (CCNU), Fotemustine, Nitrogen mustards / Oxazaphosphorines: Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil, Bendamustine Alkyl sulfonates: Busulfan Ethylene imines / Aziridines: Thiotepa, Altretamine…

Supplemental Table 2. Detailed studied population

TTT group	Diseases	Age at TTT (years)	HSCT	Received TTT	CP dose received (mg/m2)	Reason for no FP preTTT	Ovarian status post-TTT	FP post-TTT	Cumulative oocyte pick-up	Pregnancy post-TTT
G1	ABMF	35.0	allograft	RIC		CC	NA	NO		After OD
G1	IBMF	15.0	allograft	RIC		CC	DOR	NO		
G1	SCD	6.0	allograft	MAC		CC	POI	NO		
G1	SCD	4.0	allograft	MAC		CC	DOR	NO		
G1	FA	30.0	allograft	RIC		CC	DOR	NO		
G1	FA	6.0	allograft	RIC		ELGT	DOR	YES	2	
G1	FA	9.0	allograft	RIC		CC	POI	NO		
G1	B-ALL	8.0	allograft	MAC		CC	POI	NO		
G1	B-ALL	30.5	allograft	MAC		CC	NA	NO		
G1	T-ALL	33.3	allograft	RIC		ETT	POI	NO		
G1	AML	1.0	allograft	MAC		NA/NI	DOR	NO		
G1	AML	30.6	allograft	MAC		NA/NI	NA	NO		
G1	AML	26.5	autograft	MAC		ETT	POI	NO		
G1	AML	10.0	allograft	MAC		ETT	DOR	NO		
G1	CML	4.0	allograft	MAC		NA/NI	DOR	YES	0	
G1	HL	25.0	autograft	MAC		ETT	POI	NO		
G1	NHL	36.6	allograft	MAC		CC	POI	NO		
G1	NHL	21.0	autograft	MAC		NA/NI	POI	NO		
G1	NHL	25.4	autograft	MAC		ETT	POI	NO		
G2	B-ALL	15.9		FRALLE-B[1]	1000	ELGT	DOR	YES	10	
G2	B-ALL	6.0		FRALLE-B	1000	ELGT	NA	NO		
G2	B-ALL	5.0		FRALLE-B	1000	ELGT	NOR	NO		
G2	B-ALL	13.6		FRALLE-B	1000	ELGT	NA	NO		NP
G2	B-ALL	15.6		FRALLE-B	1000	ELGT	NOR	YES	18	
G2	B-ALL	15.3		FRALLE-B	1000	ELGT	NOR	NO		
G2	B-ALL	21.0		FRALLE-B	3000	ELGT	NOR	NO		
G2	B-ALL	16.0		FRALLE-B	1000	ELGT	NOR	YES	3	
G2	B-ALL	11.0		EORTC 58591[2]	4000	ELGT	NA	NO		

G2	T-ALL	15.0		FRALLE-T[1]	4000	ELGT	DOR	YES	4	
G2	T-ALL	23.0		GRAALL-2014[3]	4600	ELGT	NOR	NO		NP
G2	T-ALL	22.5		GRAALL-2014	4600	ELGT	NOR	NO		
G2	T-ALL	19.0		LL03[4]	5250	ETT	DOR	YES	6	
G2	T-ALL	26.0		GRAALL-2014	6000	ETT	DOR	NO		NP
G2	T-ALL	19.7		FRALLE-T	4000	ETT	DOR	NO		
G2	HL	24.0		BEACOPP+ABVD	1300	ELGT	DOR	NO		
G2	HL	24.6		BEACOPP+ABVD	3600	ELGT	DOR	NO		NP*
G2	HL	22.9		BEACOPP	7200	ETT	POI	NO		NP*
G2	HL	25.6		BEACOPP+ABVD	2400	ELGT	DOR	NO		NP
G2	HL	27.0		BEACOPP	3900	ELGT	DOR	NO		NP
G2	HL	26.0		BEACOPP	3600	NA/NI	DOR	NO		
G2	HL	24.0		COPDAC+ABVD	4000	NA/NI	NA	NO		
G2	HL	32.0		BEACOPP+ABVD	1300	ELGT	DOR	NO		After OD
G2	HL	30.0		BEACOPP+ABVD	1300	ELGT	DOR	NO		
G2	HL	33.8		BEACOPP	1200	ELGT	DOR	NO		NP*
G2	HL	17.9		OEPA+COPDAC	2000	ELGT	NOR	NO		
G2	HL	33.5		BEACOPP+ABVD	1300	ELGT	DOR	NO		
G2	HL	41.0		BEACOPP+ABVD	2600	NA/NI	NA	NO		
G2	NHL	26.4		R-CHOP	4500	ELGT	NOR	YES	9	
G2	NHL	30.0		R-CHOP	4500	ELGT	NOR	NO		NP
G2	NHL	18.0		Euro-LB[5]	2000	ELGT	DOR	NO		
G2	NHL	38.2		R-CHOP	4500	ELGT	POI	NO		
G3	AML	33.2		DAUNO-ARA-C	0	ELGT	NA	NO		
G3	AML	29.0		DAUNO-ARA-C	0	ELGT	NA	YES	2	NP
G3	AML	14.0		ELAM-02[6]	0	ELGT	DOR	NO		
G3	PAL	30.0		ATRA+ATO	0	CC	NOR	NO		After ART
G3	AML	22.3		DAUNO-HDAC	0	ELGT	NOR	YES	20	
G3	HL	24.0		ABVD	0	ELGT	NOR	NO		
G3	HL	29.2		ABVD	0	ELGT	DOR	YES		

ABMF: acquired bone marrow failure; ABVD: doxorubicin-bleomycin-vinblastine-dacarbazine; AML: acute myeloblastic leukemia; ARA-C: cytarabine; ART: assisted reproductive technology; ATO: Arsenic TriOxyde; ATRA: All-Trans Retinoic Acid; B-ALL: B-acute lymphoblastic leukemia; BEACOPP: bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisone; CC: clinical conditions; CML: chronic myeloid leukemia; COPDAC: cyclophosphamide-vincristine-prednisone-dacarbazine; CP: cyclophosphamide; DAUNO: daunorubicin; DOR: diminished ovarian reserve; ELGT: estimated low gonadotoxicity; ETT: emergency to treatment; FA: Fanconi anemia; FP: fertility preservation; G1: Hematopoietic stem cell transplantation; G2: Chemotherapy with bifunctional alkylating agents; G3: Chemotherapy with no bifunctional alkylating agents;

HDAC: High dose cytarabine; HL: Hodgkin lymphoma; IBMF: inherited bone marrow failure; MAC: myeloablative conditioning regimen; NA : not available; NI: no information; NHL: non-Hodgkin lymphoma; NOR: normal ovarian reserve; NP: natural pregnancy; OD: oocyte donation; OEPA: vincristine-etoposide-prednisone-doxorubicin;
POI: premature ovarian insufficiency; PAL: promyelocytic leukemia; R-CHOP: rituximab-cyclophosphamide-adriamycin-vincristine-prednisone; RIC: reduced intensity conditioning regimen; SCD: sickle cell disease; T-ALL: T-acute lymphoblastic leukemia; TTT: treatment. * >1 natural pregnancy.

1. Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. *J Clin Oncol Off J Am Soc Clin Oncol*. 2003;21(5):774-780. doi:10.1200/ JCO.2003.02.053.
2. Kicinski M, Arfeuille C, Grardel N, et al. The prognostic value of IKZF1plus in B-cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial. *Pediatr Blood Cancer*. 2023;70(6):e30313. doi:10.1002/pbc.30313.
3. Huguet F, Chevret S, Leguay T, et al. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. *J Clin Oncol Off J Am Soc Clin Oncol*. 2018;36(24):2514-2523. doi:10.1200/JCO.2017.76.8192.
4. Lepretre S, Touzart A, Vermeulin T, et al. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. *J Clin Oncol Off J Am Soc Clin Oncol*. 2016;34(6):572-580. doi:10.1200/JCO.2015.61.5385.
5.Oschlies I, Burkhardt B, Chassagne-Clement C, et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a
randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. *Am J Surg Pathol*. 2011;35(6):836-844. doi:10.1097/PAS.0b013e318213e90e.
6. Marceau-Renaut A, Duployez N, Ducourneau B, et al. Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. *HemaSphere*. 2018;2(1):e31. doi:10.1097/HS9.0000000000000031